Association of achieved LDL-C levels with global coagulability and clinical outcomes in patients with acute coronary syndrome receiving PCSK9 inhibitors: a prospective cohort study - Takeaways - MDSpire

Association of achieved LDL-C levels with global coagulability and clinical outcomes in patients with acute coronary syndrome receiving PCSK9 inhibitors: a prospective cohort study

  • By

  • Tianfu Fu

  • Song Yao

  • Shaojiang Zhang

  • Hui Linghu

  • June 10, 2026

  • 0 min

Share

  • 1

    The study evaluated the safety of achieving ultra-low LDL-C levels in ACS patients treated with PCSK9 inhibitors and DAPT.

  • 2

    Clinically relevant bleeding rates were similar between Low LDL-C (6.7%) and Non-Low LDL-C (5.0%) groups, indicating no increased bleeding risk.

  • 3

    Global coagulability and specific platelet reactivity remained stable throughout the follow-up period with no significant intergroup differences.

  • 4

    Major adverse cardiovascular events occurred in 6.7% of the Low LDL-C group compared to 13.3% in the Non-Low LDL-C group.

  • 5

    The findings support the clinical safety of profound lipid-lowering in high-risk ACS patients without increasing bleeding risk.

Original Source(s)

Related Content